Novel Scaled Average Bioequivalence Limits Based on GMR and Variability Considerations
Vangelis Karalis(National and Kapodistrian University of Athens), Panos Macheras(National and Kapodistrian University of Athens), Mira Symillides(National and Kapodistrian University of Athens)
Cited by 32
Related Papers
The Integration of Artificial Intelligence into Clinical Practice
|Applied Biosciences|2024|225
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease
|The American Journal of Medicine|2021|122
3D-Printed Oral Dosage Forms: Mechanical Properties, Computational Approaches and Applications
|Pharmaceutics|2021|78
Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA
|Pharmaceutical Research|2011|68
Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability
|Pharmaceutical Research|2008|64